KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Exchange Rate Effect (2016 - 2025)

AbbVie (ABBV) has disclosed Exchange Rate Effect for 13 consecutive years, with $11.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Exchange Rate Effect rose 123.91% to $11.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $42.0 million, a 164.62% increase, with the full-year FY2025 number at $42.0 million, up 164.62% from a year prior.
  • Exchange Rate Effect was $11.0 million for Q4 2025 at AbbVie, up from -$8.0 million in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $30.0 million in Q2 2025 to a low of -$59.0 million in Q3 2022.
  • A 5-year average of -$8.8 million and a median of -$8.5 million in 2024 define the central range for Exchange Rate Effect.
  • Peak YoY movement for Exchange Rate Effect: tumbled 783.33% in 2021, then surged 433.33% in 2025.
  • AbbVie's Exchange Rate Effect stood at -$28.0 million in 2021, then surged by 182.14% to $23.0 million in 2022, then changed by 0.0% to $23.0 million in 2023, then tumbled by 300.0% to -$46.0 million in 2024, then surged by 123.91% to $11.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Exchange Rate Effect are $11.0 million (Q4 2025), -$8.0 million (Q3 2025), and $30.0 million (Q2 2025).